AIM: To investigate the efficacy and side effects of the combined therapy of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer (ESCC) and the survival of the patients. METHODS: Sixty-four patients (median age of 63 years) with histological or cytological confirmation of ESCC received oxaliplatin 120 mg/m(2) intravenously on day 1 and capecitabine 1000 mg/m(2) orally twice daily on days 1 to 14 in a 21-d treatment cycle as palliative chemotherapy. Each patient received at least two cycles of treatment. The efficacy, side effects and patient survival were evaluated. RESULTS: The partial response (PR) rate was 43.8% (28/64). Stable disease (SD) rate was 47.9% (26/64), and disease progression rate was 15.6% (10/64). The clinical benefit rate (PR + SD) was 84.4%. The main toxicities were leukopenia (50.0%), nausea and vomiting (51.6%), diarrhea (50.0%), stomatitis (39.1%), polyneuropathy (37.5%) and hand-foot syndrome (37.5%). No grade 4 event in the entire cohort was found. The median progression-free survival was 4 mo, median overall survival was 10 mo (95% CI: 8.3-11.7 mo), and the 1- and 2-year survival rates were 38.1% and 8.2%, respectively. High Karnofsky index, single metastatic lesion and response to the regimen indicated respectively good prognosis. CONCLUSION: Oxaliplatin plus capecitabine regimen is effective and tolerable in metastatic ESCC patients. The regimen has improved the survival moderately and merits further studies.
AIM: To investigate the efficacy and side effects of the combined therapy of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer (ESCC) and the survival of the patients. METHODS: Sixty-four patients (median age of 63 years) with histological or cytological confirmation of ESCC received oxaliplatin 120 mg/m(2) intravenously on day 1 and capecitabine 1000 mg/m(2) orally twice daily on days 1 to 14 in a 21-d treatment cycle as palliative chemotherapy. Each patient received at least two cycles of treatment. The efficacy, side effects and patient survival were evaluated. RESULTS: The partial response (PR) rate was 43.8% (28/64). Stable disease (SD) rate was 47.9% (26/64), and disease progression rate was 15.6% (10/64). The clinical benefit rate (PR + SD) was 84.4%. The main toxicities were leukopenia (50.0%), nausea and vomiting (51.6%), diarrhea (50.0%), stomatitis (39.1%), polyneuropathy (37.5%) and hand-foot syndrome (37.5%). No grade 4 event in the entire cohort was found. The median progression-free survival was 4 mo, median overall survival was 10 mo (95% CI: 8.3-11.7 mo), and the 1- and 2-year survival rates were 38.1% and 8.2%, respectively. High Karnofsky index, single metastatic lesion and response to the regimen indicated respectively good prognosis. CONCLUSION:Oxaliplatin plus capecitabine regimen is effective and tolerable in metastatic ESCC patients. The regimen has improved the survival moderately and merits further studies.
Authors: Li Dong Wang; Huai Hua Yang; Zong Min Fan; Xiao Dong Lü; Jun Kuan Wang; Xiao Li Liu; Zhe Sun; Ya Nan Jiang; Xin He; Qi Zhou Journal: Cancer Detect Prev Date: 2005
Authors: A Jatoi; B R Murphy; N R Foster; D A Nikcevich; S R Alberts; J A Knost; T R Fitch; K M Rowland Journal: Ann Oncol Date: 2005-11-22 Impact factor: 32.976
Authors: James Y Tsai; David Iannitti; Anna Berkenblit; Paul Akerman; Ahmed Nadeem; Ritesh Rathore; David Harrington; Dean Roye; Thomas Miner; John M Barnett; Christine Maia; Keith Stuart; Howard Safran Journal: Am J Clin Oncol Date: 2005-08 Impact factor: 2.339
Authors: M B Polee; J Verweij; P D Siersema; H W Tilanus; T A W Splinter; G Stoter; A Van der Gaast Journal: Eur J Cancer Date: 2002-07 Impact factor: 9.162
Authors: S Lorenzen; J Duyster; C Lersch; S von Delius; M Hennig; R Bredenkamp; C Peschel; F Lordick Journal: Br J Cancer Date: 2005-06-20 Impact factor: 7.640
Authors: G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small Journal: Curr Oncol Date: 2010-08 Impact factor: 3.677
Authors: Chi Hoon Maeng; Jeeyun Lee; Paul van Hummelen; Se Hoon Park; Emanuele Palescandolo; Jiryeon Jang; Ha Young Park; So Young Kang; Laura MacConaill; Kyoung-Mee Kim; Young-Mog Shim Journal: PLoS One Date: 2012-08-03 Impact factor: 3.240
Authors: Tak Yun; Ji-Youn Han; Jin Soo Lee; Hyun Lee Choi; Hyae Young Kim; Byung-Ho Nam; Heung Tae Kim Journal: BMC Cancer Date: 2011-09-02 Impact factor: 4.430
Authors: Femke M de Man; Ruben A G van Eerden; Esther Oomen-de Hoop; Joris N Veraart; Nadia van Doorn; Leni van Doorn; Ate van der Gaast; Ron H J Mathijssen Journal: Cancers (Basel) Date: 2019-06-13 Impact factor: 6.639